Pricing Log in Create free account
Friday 6 November 2026 Export CC’s income statement to Excel — free account

The Chemours Company

CC Basic Materials Specialty Chemicals

The Chemours Company’s revenue for fiscal 2025 (year ended December 2025) was $5.8 billion, roughly unchanged from fiscal 2024.

Revenue
+3.01%
EPS
+223.8%
Free cash flow
−12.5%
Total debt
−7.64%

Quarter to September 2026, against a year earlier

12.82 0.97 −7.03%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−9.0×
Dividend yield
2.73%
F-score
4/9
Altman Z
1.35
Beneish M
−2.91
Dividend safety
0/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.49
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — 7 — — —
Sell — — — — — — — — — — — —
Insider Ownership 1.51%

Capital & Financial Ratios $m

Size
Market Cap 1,920.00
Revenue ttm 5,842.00
Net income ttm (154.00)
Free cash flow ttm 204.00
Net debt Q 3,094.00
Valuation
P/E 0.00
Forward P/E (8.96) (negative: loss-making)
Price / sales 0.33
Forward P/S Powerpack
Price / FCF 9.51
Price / book 12.44 (above 6: high)
Financial health
Current ratio Q 1.81 (at or above 1.5: strong)
Debt / equity Q 24.57 (above 2: weak)
Interest coverage Q 3.32
Growth
Revenue growth Q +3.01% (above 0%: growing)
Operating income growth Q +143.62% (above 0%: growing)
EPS, this year −10.10% (below 0%: weak)
EPS, next year A +107.95% (at or above 15%: strong)
Revenue, next year A +1.84%
EPS, past 5 yrs —
EPS, next 5 yrs A +32.49% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.9×, against a ten-year median of 1.1×; over the ten years it ranged from 0.8× in 2016 to 2.2× in 2017.
P/S against its own 10 years 11.07%
10-year low 10-year high
P/B against its own 10 years 87.50%
10-year low 10-year high
EV/Sales against its own 10 years 3.08%
10-year low 10-year high
EV/FCF against its own 10 years 50.05%
10-year low 10-year high

Dividends

Yield
2.73%
Annual rate
0.35
Payout ratio
—
Growth, 2018–26
−10.4%/yr
  1. 0.84 ’18
  2. 1.00 ’19 +19
  3. 1.00 ’20 +0
  4. 1.00 ’21 +0
  5. 1.00 ’22 +0
  6. 1.00 ’23 +0
  7. 1.00 ’24 +0
  8. 0.51 ’25 −49
  9. 0.35 ’26 −32
paid change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,807 713 672 739
Receivables 610 770 679 922
Inventory 1,352 1,463 1,569 1,475
Other — — 1 1
3,835 3,017 3,001 3,219
2023 2024 2025 Q'26
Payables 1,159 1,156 954 995
ST’ Debt 51 54 42 50
Other 218 214 184 203
2,486 1,820 1,686 1,777

Compound Annual Growth %

10y 5y 3y
Sales 0.16% 3.17% (5.26%)
Cash Flow 3.79% (20.03%) (29.55%)
Earnings 0.00% 0.00% 0.00%
Book Value 6.80% (20.99%) (39.02%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.26 Actual 0.21

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.00 0.05 Beat by 0.05
Q1 FY26 −0.05 0.05 Beat by 0.10
Q2 FY26 0.43 0.42 Miss by 0.01
Q3 FY26 0.26 0.21 Miss by 0.05
Q4 FY26 0.14 — Reports 18 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.19) (1.81) 1.29 — —
’25 (0.03) (2.54) 0.40 (0.31) (2.56)
’24 0.34 0.39 (0.22) (0.09) 0.46
’23 0.96 (2.52) 0.08 (0.21) (1.70)
’22 1.43 1.26 1.52 (0.64) 3.65
’21 0.57 0.39 1.27 1.40 3.60
’20 0.61 0.15 0.46 0.11 1.32
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1,381 1,591 1,540 — —
’25 1,368 1,615 1,495 1,330 5,808
’24 1,362 1,554 1,508 1,358 5,782
’23 1,536 1,643 1,487 1,412 6,078
’22 1,764 1,915 1,777 1,375 6,831
’21 1,436 1,655 1,680 1,574 6,345
’20 1,305 1,093 1,233 1,338 4,969
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (44) 158 149 — —
’25 (112) 93 146 137 264
’24 (290) (620) 139 138 (633)
’23 (124) 67 131 482 556
’22 2 291 301 161 755
’21 39 256 311 208 814
’20 44 111 299 353 807
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (93) 114 98 — —
’25 (196) 50 112 85 51
’24 (389) (693) 63 26 (993)
’23 (215) 9 183 209 186
’22 (104) 229 229 127 481
’21 (21) 189 244 125 537
’20 (62) 50 252 300 540
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 5,400 6,183 6,638 5,526 4,969 6,345 6,831 6,078 5,782 5,808 5,842 +0.8% 5,915 6,196 6,437 +3.5%
Gross margin, % 20.43 28.22 29.69 19.24 21.47 21.77 23.66 21.42 19.75 15.53 15.13 (4.9) pt
EBT (11) 912 1,155 (124) 179 676 741 (318) 106 (277) 119 +43.1%
EBT margin, % (0.20) 14.75 17.40 (2.24) 3.60 10.65 10.85 (5.23) 1.83 (4.77) 2.04 (4.6) pt
Net income 7 747 996 (52) 219 608 578 (252) 69 (386) (154) n/m
Per share, $
Per share, $ Revenue 29.73 33.45 37.51 33.53 30.17 38.47 43.97 40.82 38.68 38.66 38.60 +3.0%
Earnings 0.04 4.04 5.62 (0.32) 1.33 3.69 3.72 (1.70) 0.46 (2.57) (1.02) n/m
Cash flow 3.27 3.46 6.44 3.94 4.90 4.94 4.86 3.73 (4.23) 1.76 2.64 (6.7%)
Capex (1.86) (2.22) (2.81) (2.92) (1.62) (1.68) (1.76) (2.48) (2.41) (1.42) (1.30) (3.0%)
Free cash flow 1.41 1.24 3.63 1.03 3.28 3.26 3.10 1.25 (6.64) 0.34 1.35 (14.6%)
Book value 0.57 4.68 5.76 4.22 4.95 6.56 7.13 4.96 3.83 1.67 1.03 +12.6%
Shares, m 182 185 177 165 165 165 155 149 149 150 151 (2.1%)
Valuation, ×
Valuation, × P/E 530.50 12.81 5.04 0.00 18.50 9.05 8.41 0.00 38.29 0.00 0.00 62.3
P/S 0.71 1.55 0.75 0.54 0.82 0.87 0.70 0.78 0.44 0.31 0.33 0.7
P/B 37.06 11.06 4.90 4.29 5.01 5.12 4.30 6.40 4.42 7.06 12.44 9.0
EV/Sales 1.20 1.96 1.17 1.12 1.41 1.23 1.07 1.15 1.03 0.90 0.86 1.2
EV/FCF 25.38 52.93 12.10 36.68 12.97 14.59 15.15 37.44 (5.97) 102.75 24.68 30.4
Cash, $m
Cash, $m Operating cash flow 594 640 1,140 650 807 814 755 556 (633) 264 400 (8.6%)
Capex (338) (411) (498) (481) (267) (277) (274) (370) (360) (213) (196) (5.0%)
Free cash flow 256 229 642 169 540 537 481 186 (993) 51 204 (16.4%)
Balance, $m
Balance, $m Working capital 782 1,845 1,584 1,236 1,191 1,487 1,323 1,349 1,197 1,315 1,442 +5.9%
Net debt 2,642 2,556 2,771 3,217 2,921 2,298 2,531 2,231 3,400 3,469 3,094 +3.1%
Shareholders’ equity 104 865 1,020 695 815 1,082 1,107 739 572 251 156 +10.3%
Returns, %
Returns, % ROA 0.11 11.17 13.58 (0.71) 3.05 8.31 7.61 (3.18) 0.88 (5.18) (2.07) (5.3) pt
ROIC (2.14) 17.92 19.50 5.56 6.14 12.50 13.26 (5.16) 5.02 (1.08) 0.44 +1.1 pt
ROE 5.98 153.97 105.57 (6.06) 29.01 64.10 52.81 (27.41) 10.53 (93.80) (67.54) (99.8) pt
People
People Employees 7,000 7,000 7,000 7,000 6,500 6,400 6,600 6,200 6,000 5,700 — (2.3%)
Revenue/emp, $m 0.77 0.88 0.95 0.79 0.76 0.99 1.04 0.98 0.96 1.02 — +3.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

The Chemours Company vs peers in Specialty Chemicals (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
WDFC WD-40 Company $3.0B 37.0× 32.3× +8.14% (above 0%: growing) −31.85% (below 0%: shrinking) +63.49% (above 0%: growing) 52.78% 10.78% Compare
FUL H. B. Fuller Company $2.7B 13.8× 11.7× +5.17% (above 0%: growing) +18.19% (above 0%: growing) −58.41% (below 0%: shrinking) 33.22% 12.07% Compare
KWR Quaker Houghton $2.6B 27.2× 21.6× +10.27% (above 0%: growing) −0.42% (below 0%: shrinking) −92.40% (below 0%: shrinking) 35.54% 8.97% Compare
NGVT Ingevity Corporation $2.2B 42.0× 18.4× −5.25% (below 0%: shrinking) n/m −136.08% (below 0%: shrinking) 44.25% 19.13% Compare
IOSP Innospec Inc. $2.0B 13.9× 19.5× +7.17% (above 0%: growing) +146.71% (above 0%: growing) −88.68% (below 0%: shrinking) 27.26% 8.80% Compare
MTX Minerals Technologies Inc. $1.9B — (loss-making) — (loss-making) +4.23% (above 0%: growing) +2.80% (above 0%: growing) +19.04% (above 0%: growing) 23.28% 11.68% Compare
CC The Chemours Company $1.9B — (loss-making) — (loss-making) +3.01% (above 0%: growing) +223.80% (above 0%: growing) −12.50% (below 0%: shrinking) 15.00% 14.87%
STDN Standard Nuclear Inc $1.8B — — — n/m — 67.21% (90.70%) Compare
SCL Stepan Company $1.5B 361× — (loss-making) +17.26% (above 0%: growing) +65.47% (above 0%: growing) −4.42% (below 0%: shrinking) 12.65% 3.75% Compare
Median of peers $2.1B 32.1× 19.5× +7.17% +10.50% −58.41% 34.38% 9.88%

All 61 Specialty Chemicals stocks →

Pay and ownership Proxy statement filed 10 March 2026

Ownership

Directors and executive officers, together less than 1%
BlackRock, Inc 16.81%
The Vanguard Group 11.76%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

The Chemours Company (CC) Latest News

5 Nov

Impact 3 · · GuruFocus.com

3 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · Moby

2 Nov

Impact 3 · · PR Newswire

20 Oct

Impact 4 · · Simply Wall St.

19 Oct

Impact 3 · · PR Newswire

13 Oct

Impact 4 · · Investing.com
Impact 3 · · MT Newswires

29 Sep

Impact 3 · · Zacks

17 Sep

Impact 4 ·

16 Sep

Impact 3 ·

11 Sep

Impact 4 · · manufacturingdive.com

10 Sep

Impact 4 ·
Impact 4 ·
Impact 3 · · InvestorsHub

3 Sep

Impact 4 ·

14 Aug

Impact 4 ·

11 Aug

Impact 3 · · The Motley Fool transcript

10 Aug

Impact 4 ·
Impact 3 ·

5 Aug

Impact 4 · · The Motley Fool
Impact 4 · · Moby
Impact 3 · · MarketBeat transcript
Impact 3 ·

4 Aug

Impact 3 ·
Impact 3 ·

29 Jul

Impact 3 ·

28 Jul

Impact 3 ·

2 Jul

Impact 4 ·

CC metrics, ten years each

stockrow.com/CC · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com